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Abstract
Background: Current practice for patients with breast cancer referred for genetic counseling, includes face-to-face
consultations with a genetic counselor prior to and following DNA-testing. This is based on guidelines regarding
Huntington’s disease in anticipation of high psychosocial impact of DNA-testing for mutations in BRCA1/2 genes.
The initial consultation covers generic information regarding hereditary breast cancer and the (im)possibilities of
DNA-testing, prior to such testing. Patients with breast cancer may see this information as irrelevant or unnecessary
because individual genetic advice depends on DNA-test results. Also, verbal information is not always remembered
well by patients. A different format for this information prior to DNA-testing is possible: replacing initial face-to-face
genetic counseling (DNA-intake procedure) by telephone, written and digital information sent to patients’ homes
(DNA-direct procedure).
Methods/design: In this intervention study, 150 patients with breast cancer referred to the department of Clinical
Genetics of the Radboud University Nijmegen Medical Centre are given the choice between two procedures,
DNA-direct (intervention group) or DNA-intake (usual care, control group). During a triage telephone call, patients
are excluded if they have problems with Dutch text, family communication, or of psychological or psychiatric
nature. Primary outcome measures are satisfaction and psychological distress. Secondary outcome measures are
determinants for the participant’s choice of procedure, waiting and processing times, and family characteristics. Data
are collected by self-report questionnaires at baseline and following completion of genetic counseling. A minority
of participants will receive an invitation for a 30 min semi-structured telephone interview, e.g. confirmed carriers of
a BRCA1/2 mutation, and those who report problems with the procedure.
Discussion: This study compares current practice of an intake consultation (DNA-intake) to a home informational
package of telephone, written and digital information (DNA-direct) prior to DNA-testing in patients with breast
cancer. The aim is to determine whether DNA-direct is an acceptable procedure for BRCA1/2 testing, in order to
provide customized care to patients with breast cancer, cutting down on the period of uncertainty during this
diagnostic process.
Trial registration: The study is registered at the Dutch Trial Registry www.trialregister.nl (NTR3018).
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Background
Patients with breast cancer at high risk of an underlying
hereditary predisposition face a time-consuming diagnostic
process of several months: it might be helpful to be able to
cut down on this long period of uncertainty and provide
information applicable to their personal situation as early
as possible. Having personal experience with breast cancer,
these patients are likely to have enhanced personal risk
estimates, thus a higher expectation for protective actions
such as longer or more intensive surveillance [1]. Should
they carry a pathogenic mutation in either the BRCA1 or
BRCA2 gene, these patients do have a considerable long
term risk for developing a second primary breast cancer
(either ipsi- or contralateral) of up to 60% [2-4]. Women
recently diagnosed with breast cancer may want to take
their BRCA1/2 status into consideration for their choice of
surgical treatment (i.e. breast-conserving with radiotherapy
versus ipsi/contralateral mastectomy) and, in the near fu-
ture, chemotherapy (i.e. PARP-inhibitors) [5-10]. BRCA1/2
mutation carriers face an additional risk of ovarian cancer
ranging from 20-60% for BRCA1 and 2-20% for BRCA2
[2-4]. As screening for ovarian cancer through yearly
serum CA-125 measurements and transvaginal ultrasound
has proven to be ineffective [11-13], clinicians strongly rec-
ommend prophylactic bilateral salpingoophorectomy
(pBSO) around the age of 35 to 40 years [13]. pBSO
reduces the risk of ovarian cancer by 80-90%, and in un-
affected premenopausal women simultaneously reduces
breast cancer risk by 50% [14,15].
Patients with breast cancer often express concern and
uncertainty regarding the risk of breast cancer for their
unaffected relatives, especially their sisters and daughters
[16]. For unaffected relatives carrying a BRCA1/2 muta-
tion, cumulative breast cancer risk at the age of 70 years
ranges from 40-80% [2-4]. At the age of 25 years, they
may choose between an intensive breast cancer screening
program consisting of yearly MRI scans, mammography
and clinical breast examinations [17,18] or undergoing
prophylactic surgery, reducing the risk for breast cancer
by 90% [19-21]. Some carriers may still be at an age to
be confronted with childbearing conflicts [22]. These are
only a few of the life-changing decisions for both
patients with breast cancer and their relatives dependent
on the results of DNA-testing, which may or may not
confirm the presence of a genetic predisposition for
breast and ovarian cancer. A previous study in Dutch
patients being evaluated for possible breast cancer
showed that these patients experienced the period before
the final diagnosis as the most stressful, regardless of
whether they had received a benign or cancer diagnosis
afterwards [23]. This same principle likely applies to
BRCA1/2 testing. Reducing the period of uncertainty in
the diagnostic process and offering various forms of in-
formation might help substantially.
Another attempt to speed up the diagnostic process con-
cerning hereditary cancer was previously introduced in the
evaluation of hereditary colon cancer in the Netherlands.
Pathologists are now able to test tumor material of patients
younger than 50 years for microsatellite instability (MSI)
and immunohistochemical staining of gene products,
which may reveal a high a priori risk for an underlying
genetic predisposition, without prior consultation of a gen-
etic counselor. If these characteristics are present, patients
are referred for further evaluation by a genetic counselor
[24,25]. This so-called MIPA procedure (MSI-test by
pathologists) is seen by patients as a valuable addition to
the diagnostic process of hereditary colon cancer, without
feeling either overwhelmed or underinformed, nor showing
increased levels of psychosocial distress [26-28].
Such an intervention may also be applicable to patients
with breast cancer. As there is no equivalent of tumor ma-
terial testing in hereditary breast cancer, alternatives for
modification must be found within the current diagnostic
process. Genetic testing for hereditary breast cancer
includes genetic counseling both prior to and following
DNA-testing, based on guidelines regarding presympto-
matic testing for Huntington’s disease (HD) [29-31]. This
approach had been adopted for hereditary breast cancer
due to concerns about the psychological consequences of
BRCA1/2 genetic susceptibility testing [32]. However, ex-
tensive prior research shows there is no significant long
term psychological impact: after an initial increase follow-
ing BRCA1/2 testing, psychosocial distress returns to pre-
testing levels over time [33-39]. Therefore, in the case of
hereditary breast cancer where protective measures are
possible, it may not be necessary to adhere to such a strict
counseling protocol as defined for an untreatable neurode-
generative disorder such as HD [32]. Patients with breast
cancer express the most interest in answers regarding their
personal situation: Is my breast cancer of hereditary origin
and what are my children’s risks [submitted data by S. Sale-
mink]? Answers to these questions cannot be given until
the results of DNA-testing are known. During the initial
face-to-face consultation, patients are provided with gen-
eral information regarding hereditary breast cancer, DNA-
testing and possible consequences, prior to actual DNA-
testing. Patients consider this generic information less rele-
vant than the personal advice in the second consultation
post DNA-testing and may thus experience this intake as
an unnecessary delay [40]. It is also widely known that
about 40 to 80% of verbal information is immediately for-
gotten by patients [41]. A recent study in Canada offered a
group of Jewish women DNA-testing through written and
telephone invitation. The majority of these women had
positive experiences with this approach and considered it
to be effective [42]. Providing patients with alternative
means to educate themselves regarding hereditary breast
cancer and DNA-testing, prior to their decision to undergo
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testing, might improve patient recollection of medical in-
formation as well as increase patient participation.
Therefore, this study offers patients with breast cancer
the choice of replacing the initial face-to-face consultation
prior to DNA-testing (usual care DNA-intake procedure)
by a home information package including telephone, writ-
ten and digital information consisting of a website and
educational movie (DNA-direct procedure). DNA-testing
will thus be performed prior to genetic counseling, con-
trary to current practice. At the first face-to-face contact,
counselors will be able to disclose DNA-results and custo-
mized advice to patients. This eliminates extraneous infor-
mation which is not applicable to the individual patient,
and provides patients with the information they desire in a
quick and patient-centric manner.
The aim of this intervention study is to compare this new
DNA-direct procedure to current practice (DNA-intake
procedure). The effects of the DNA-direct procedure on the
experience and psychosocial distress on patients with breast
cancer, as well as the speed and quality of genetic advice,
will be evaluated. The hypothesis is that undergoing the
DNA-direct procedure does not lead to increased levels of
psychosocial distress as compared to the usual care DNA-
intake procedure, with equal levels of patient satisfaction
plus shorter waiting and processing times. A trend similar
to traditional BRCA1/2 testing – a short term increase in
distress, falling back to pre-testing levels over time [33-39]
– is expected in the DNA-direct procedure. This would
make DNA-direct an acceptable procedure for patients with
breast cancer undergoing genetic testing, with the goal of
more customized care, and a shorter period of uncertainty.
Moreover, it would facilitate taking genetic advice into ac-
count for the treatment and follow-up of breast cancer.
Methods/design
Design
The study examines the effect of the DNA-direct procedure
on the experience and psychological distress of patients with
breast cancer as well as several secondary outcome mea-
sures, including waiting and processing times, as compared
to the current DNA-intake procedure. Two groups will be
compared: the intervention group, who choose to undergo
the DNA-direct procedure, and the control group, who will
receive care as usual (DNA-intake procedure). Participants
may choose freely between the DNA-direct versus DNA-in-
take procedures. This study is not randomized due to the
wish to evaluate whether there is indeed a desire for the
proposed DNA-direct procedure amongst patients with
breast cancer, and to evaluate the reasons stated for prefer-
ring one procedure over the other.
Ethical consideration
The study has been approved by the medical ethical
committee of the Radboud University Nijmegen Medical
Centre. Full medical ethical approval has been obtained
in July 2011.
Study sample
All female patients previously or currently diagnosed with
breast cancer and referred to the department of Clinical
Genetics of the Radboud University Nijmegen Medical
Centre from August 9th 2011 are eligible for inclusion. Re-
cruitment will continue until the desired total of 150 parti-
cipants is reached. Patients who have problems reading
Dutch text, problems with family communication or pro-
blems of psychological/psychiatric nature (including
current use of related medication) will be excluded.
Recruitment
Patients are sent a written letter by a trained doctor an-
nouncing a phone call, in which the two choices of pro-
cedure are explained (DNA-intake for a face-to-face
intake consultation prior to DNA-testing, versus DNA-
direct for a home package of telephone, written and
digital information) and exclusion criteria are checked.
The aim of this telephone approach is triage: by checking
for exclusion criteria such as psychological problems,
patients who aren’t deemed suitable for DNA-direct (due
to its dependency on the patient’s own decision making
ability) are filtered out and instead invited for a regular
intake consultation, where further psychosocial support
is immediately available prior to DNA-testing. Genetic
counseling is not offered by phone: questions of this na-
ture are deferred to the personal consultations. The tri-
age phone call has been thoroughly practiced (over 20
times) by the involved doctor with people both specia-
lized and not specialized in clinical genetics.
All patients receive the same two questionnaires, one
at inclusion (baseline) and one after completion of the
chosen genetic counseling procedure (follow-up).
Patients who are confirmed carriers of a BRCA1/2 muta-
tion, patients reporting problems with the chosen pro-
cedure, and randomly selected (n = 10) patients will be
invited for a 30 min semi-structured telephone interview.
BRCA1 and BRCA2 genetic testing
The coding sequences and intron/exon boundaries of
BRCA1 and BRCA2 are analyzed by sequence analysis
(primer sequences available on request). Gross deletions
and duplications in the BRCA1 gene are detected by
multiplex ligation-dependent probe amplification (MRC-
Holland, Amsterdam, kit P002-C2). All findings are con-
firmed by an independent test.
Intervention
Patients who choose the DNA-direct procedure, receive a
home informational package including an informational
letter, a link to a website including a short educational
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movie about hereditary breast cancer and DNA-testing.
Also included are two EDTA blood vials with informed
consent and family history forms. Patients are instructed
to call their family doctor assistant to ask where to have
their blood drawn, then return the vials plus signed forms
in the appropriate return package. An appointment for a
personal consultation to disclose results is set 8 weeks after
DNA-testing has commenced.
All patients (whether they choose DNA-direct or
DNA-intake) are seen by one of five selected genetic
counselors, each of whom has extensive experience in
genetic counseling for hereditary cancer. These counse-
lors have had multiple meetings in order to structure the
DNA-direct consultations as follows: If no mutation is
found, further screening advice is formulated based on
familial risk scores: FHAT [43], Myriad [44] and Claus/
van Asperen [45,46]. Further evaluation of family history
and features of other hereditary cancer syndromes may
be required. In the case of a pathogenic BRCA1 or
BRCA2 mutation, this result is disclosed immediately,
first allowing the patient to react, followed by an explan-
ation of the consequences, including prevention mea-
sures and family evaluation. If considered necessary, a
second consultation is offered for further genetic coun-
seling. All confirmed BRCA1/2 carriers will be
approached by a social worker to extend psychosocial
support if needed, as in usual care.
Study outcomes
Participants are asked to fill out a questionnaire twice: at
baseline and following the conclusion of genetic counsel-
ing and/or testing (follow-up). Some measures are used
in both questionnaires, while others are only included in
either baseline or follow-up.
Primary outcomes
Choice of procedure
Percentages of patients choosing one procedure over the
other (ratio between the two groups) is determined to
assess the desirability of the new DNA-direct procedure.
Psychological burden (baseline and follow-up)
Quality of Life To measure global health-related quality
of life (QoL), two items scored on a scale of 1-7 were
selected from the EORTC-Q30. The full EORTC-Q30
has been widely used and validated for cancer research
[47]. The two global QoL items have an excellent in-
ternal consistency as proven by the reported Cronbach’s
α of 0.91 [48].
General health The 12-item version of the General
Health Questionnaire (GHQ-12) is used as a measure of
general psychological distress, using GHQ-scoring of
0,0,1,1 per item (range 0-12) with a threshold of ≥4 to
identify ‘caseness', recommended for patients with breast
cancer. The GHQ-12 is the shortest version of all GHQs
and recommended for research use, with good internal
consistency (Cronbach’s α= 0.82 - 0.86) [49-51].
Cancer specific distress The Impact of Event Scale
(IES) measures cancer specific distress [52,53] and is
included in baseline once using genetic predisposition
for cancer as the distressing event, once using breast
cancer. For follow-up, only genetic predisposition is
included. The IES consists of 15 items, each scored
0,1,3,5. A total score of 9-25 or ≥26 reflects moderate or
serious adaptation difficulties respectively. The Dutch
version of the IES has a good internal consistency with a
Cronbach’s α of 0.87 to 0.96 [53].
Risk perception Risk perception of a genetic predispos-
ition for breast cancer, as well as breast cancer recur-
rence, is measured on a scale of 0-100.
Cancer worry scale To measure fear of cancer recur-
rence, the 8-item Cancer Worry Scale (CWS) is included,
which has previously been used in studies among cancer
patients. Each item is scored 1,2,3,4 from 1 ‘almost
never’ to 4 ‘almost always’, the total score ranging from
8-32. It has a good internal consistency with a Cron-
bach’s α of 0.80 [54-56].
Experiences with genetic counseling (follow-up)
Decisional conflict The difficulty of decision-making, in
this study defined as whether or not to undergo genetic
testing, is assessed using the traditional format of the
Decisional Conflict Scale; 1 item (“I expect to stick to
my decision”) is left out as it is not applicable to DNA-
testing [57-59]. 15 items scored 0,1,2,3,4 from 0 ‘strongly
agree’ to 4 ‘strongly disagree’ remained, including “I am
satisfied with my decision” which is also used separately
for overall satisfaction. Scores are summed, divided by
15 and multiplied by 25, resulting in a range from 0 to
100. Scores below 25 are considered as ‘no decisional
conflict’, between 25 and 37.5 as ‘moderate conflict’ and
exceeding 37.5 as ‘severe conflict’. The DCS has good in-
ternal consistency exceeding 0.78 [57-59].
Satisfaction with choice Knowledge of hereditary breast
cancer following versus prior to the chosen genetic
counseling procedure, as well as the amount and quality
of information received, is rated on a scale of 1-6. Parti-
cipants answer ‘yes’, ‘no’ or ‘don’t know’ for choosing
DNA-testing and/or DNA-direct if given a second
chance or asked to give advice to other women in a simi-
lar situation.
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Satisfaction with genetic counseling The Dutch Na-
tional Institute for Public Health and the Environment
(RIVM) developed a standard questionnaire to measure
satisfaction with the service (18 items) and information (8
items) expected of a genetic counselor. Each item is scored
on a Likert-scale 1-4, total scores range from 26-104.
Open-ended questions evaluate positive/negative experi-
ences during the chosen genetic counseling procedure.
Secondary outcomes
General information (baseline)
Demographical and breast cancer information Data
are gathered on age, education level, work status, marital
and parental status, cancer status, medical information
need (scale 1-10), use of breast cancer information
resources and type of information previously given by
their referring physician.
Empowerment (baseline) Empowerment is the process
in which patients discover and utilize their own power,
which will be measured using the Cancer Empowerment
Questionnaire (CEQ). It consists of 40 items, each scored
on a Likert-scale of 1-5 (1 ‘strongly disagree’, 5 ‘strongly
agree’). Four factors are identified: ‘Personal Strength’, ‘So-
cial Support’, ‘Community’ and ‘Health Care’. A good in-
ternal consistency (Cronbach’s α=0.94) was demonstrated
for all four factors and the total Empowerment scale [60].
Experiences with genetic counseling and testing (follow-up)
Choice of procedure Participants describe reasons for
choosing DNA-direct or DNA-intake.
Family relations Three categories of family members
are defined: 1) nuclear family, being partner and/or chil-
dren; 2) family of origin, being parents, brothers and/or
sisters; and 3) aunts and female cousins on the family
side where breast cancer is prevalent, being the second
generation relatives most likely to be affected by genetic
testing of the patient. Participants report the frequency
of contact with each category of relatives, as well as indi-
cate the quality of their relationship on a scale of 1-10.
Family communication For each above-mentioned rela-
tive, participants indicate whether, and if so, when (dir-
ectly after information, just before DNA-result, after
DNA-result) and how often (on a scale of 1-5), they had
spoken to this relative about hereditary breast cancer.
Also included is the Openness to Discuss Hereditary
Cancer in the Family scale (ODHCF) which consists of 7
items each scored 1,2,3,4 with a range 7-24: once for the
nuclear family (α= 0.79) and once for the family of origin
(α= 0.93) [61].
Other measures
Waiting and processing times, as well as family pedigree
characteristics, are also gathered.
Sample size calculation
For this intervention study, participants are not rando-
mized into groups, but given their own choice. This leads
to certain complications when it comes to a formal power
calculation. First, the ratio between the two procedures is
unknown: this may either be balanced (50% versus 50%) or
unbalanced (e.g. 20% versus 80%). Second, due to not ran-
domizing, the results will have to be corrected for multiple
confounders, which are not all known at this point. The
sample size, based on aforementioned ratio between both
groups (choice of procedure), needs to be large enough to
be able to integrate these confounders into a regression
model. Using a power of 80% and a two-tailed probability
level for statistical significance testing of 0.05, while taking
into account group ratios ranging from balanced (50% ver-
sus 50%) versus unbalanced (to an estimated maximum of
20% versus 80%), the total sample size has been set to 150
patients with breast cancer.
Statistical analysis
To compare general characteristics, baseline and follow-
up results between the intervention versus control group,
the unpaired t-test will be used for continuous variables,
Mann–Whitney U test for non-parametric variables and
chi-square test for dichotomous variables. For the com-
parison of baseline versus follow-up results within each
group, the paired t-test will be used for continuous, Wil-
coxon test for non-parametric and McNemar’s test for
dichotomous variables. Multivariate analysis will consist
of a regression model using the follow-up results as out-
come (dependent) variables, to be compared between the
intervention versus control groups as independent vari-
ables, with the baseline results as covariates supplemen-
ted by variables that were found to be statistically
significant in previous univariate analyses. The probabil-
ity level for statistical significance testing is set at 0.05
(two-tailed). The SPSS 18.0 statistical package will be
used to analyze the data.
Discussion
Considering today’s call for more patient participation in
medical decision-making, the convenience of taking up
information and drawing blood close to home, paired
with customized advice from the very first consultation,
might appeal to patients. Replacing the face-to-face in-
take consultation with a genetic counselor by a home in-
formational package of telephone, written and digital
information might speed up the diagnostic process of
hereditary breast cancer and reduce extraneous informa-
tion. For example, this would allow patients to go over
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this information at their own convenience and in their
own homes. It could possibly reduce travel efforts to a
hospital as well as time conflicts with breast cancer
therapy.
However, there are certain downsides compared to
traditional genetic testing. All patients with breast cancer
referred to clinical genetics by their treating physician
are eligible for the DNA-direct procedure. This means
that even those patients who would not normally fulfill
criteria for BRCA1/2 testing are now able to have their
blood drawn for DNA-testing, regardless of those cri-
teria. In the DNA-intake procedure, patients who do not
fulfill the aforementioned criteria will not be offered fur-
ther DNA-testing. This may lead to a selection bias. Our
intention is to compare DNA-direct to current practice:
adhering to these criteria is the current practice and
must be reflected in the DNA-intake procedure.
Additionally, genetic counselors must adjust their coun-
seling styles to the disclosure of the DNA-results being the
first order of business, without having built up a counselor-
patient relationship beforehand. New information might
come forward following result disclosure, leading to ad-hoc
modification of screening advice. For this reason, as well as
to avoid intercounselor variation, we have selected five gen-
etic counselors with many years of experience in oncoge-
netic counseling to see all patients participating in this
study (both DNA-direct and DNA-intake).
In conclusion, the aim of our study is to determine
whether DNA-direct is an acceptable procedure for
BRCA1/2 testing, in order to provide customized care to
patients with breast cancer and remove unnecessary
waiting times within the diagnostic process, cutting
down on the long period of uncertainty that patients are
currently faced with.
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